Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 5 studies | 30% ± 7% | |
epithelial cell | 4 studies | 32% ± 10% | |
ciliated cell | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 1507.34 | 328 / 328 | 100% | 15.79 | 178 / 178 |
liver | 100% | 8677.27 | 226 / 226 | 100% | 46.59 | 405 / 406 |
intestine | 100% | 2813.81 | 966 / 966 | 100% | 19.94 | 525 / 527 |
thymus | 100% | 2234.85 | 653 / 653 | 100% | 21.43 | 602 / 605 |
prostate | 100% | 1918.94 | 245 / 245 | 99% | 26.55 | 499 / 502 |
uterus | 100% | 1335.91 | 170 / 170 | 99% | 15.84 | 456 / 459 |
kidney | 100% | 3699.31 | 89 / 89 | 99% | 17.49 | 894 / 901 |
esophagus | 100% | 1209.63 | 1439 / 1445 | 99% | 17.10 | 182 / 183 |
ovary | 99% | 1560.56 | 179 / 180 | 100% | 16.25 | 428 / 430 |
breast | 100% | 1731.74 | 459 / 459 | 99% | 22.87 | 1106 / 1118 |
brain | 99% | 1003.54 | 2603 / 2642 | 100% | 14.23 | 705 / 705 |
skin | 100% | 2006.31 | 1809 / 1809 | 99% | 15.55 | 465 / 472 |
bladder | 100% | 1462.29 | 21 / 21 | 98% | 19.83 | 496 / 504 |
stomach | 100% | 1606.77 | 359 / 359 | 98% | 17.92 | 281 / 286 |
lung | 99% | 1313.40 | 575 / 578 | 99% | 17.92 | 1140 / 1155 |
adrenal gland | 100% | 14606.82 | 258 / 258 | 96% | 19.26 | 221 / 230 |
adipose | 100% | 1200.62 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 21.64 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.88 | 29 / 29 |
spleen | 100% | 1657.44 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 14.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 22.95 | 1 / 1 |
blood vessel | 99% | 1027.01 | 1323 / 1335 | 0% | 0 | 0 / 0 |
muscle | 96% | 677.53 | 768 / 803 | 0% | 0 | 0 / 0 |
heart | 93% | 586.31 | 802 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 89% | 1238.92 | 830 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061624 | Biological process | fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate |
GO_0045088 | Biological process | regulation of innate immune response |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0046835 | Biological process | carbohydrate phosphorylation |
GO_0019563 | Biological process | glycerol catabolic process |
GO_0039534 | Biological process | negative regulation of MDA-5 signaling pathway |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0034012 | Molecular function | FAD-AMP lyase (cyclizing) activity |
GO_0050354 | Molecular function | triokinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004371 | Molecular function | glycerone kinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | TKFC |
Protein name | Triokinase and FMN cyclase Triokinase/FMN cyclase (Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)) [Includes: ATP-dependent dihydroxyacetone kinase (DHA kinase) (EC 2.7.1.28) (EC 2.7.1.29) (Glycerone kinase) (Triokinase) (Triose kinase); FAD-AMP lyase (cyclizing) (EC 4.6.1.15) (FAD-AMP lyase (cyclic FMN forming)) (FMN cyclase)] DAK protein Triokinase/FMN cyclase (EC 2.7.1.28) (EC 2.7.1.29) (EC 4.6.1.15) (Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing)) |
Synonyms | DAK |
Description | FUNCTION: Catalyzes both the phosphorylation of dihydroxyacetone and of glyceraldehyde, and the splitting of ribonucleoside diphosphate-X compounds among which FAD is the best substrate. Represses IFIH1-mediated cellular antiviral response . . |
Accessions | E9PJG8 ENST00000534084.1 ENST00000524968.1 ENST00000394900.8 [Q3LXA3-1] E9PQR1 A0AUP5 I3L252 Q3LXA3 ENST00000529479.5 H0YCY6 ENST00000532173.6 |